|
시장보고서
상품코드
2016656
분지병변 시장 보고서 : 유형별, 용도별, 지역별(2026-2034년)Bifurcation Lesions Market Report by Types (One-Stent, Two-Stent), Application (Coronary Vascular, Peripheral Vascular), and Region 2026-2034 |
||||||
세계의 분지병변 시장 규모는 2025년에 26억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 39억 달러에 달하며, 2026-2034년에 CAGR 4.22%로 성장할 것으로 예측하고 있습니다.
분지부 병변이란 주요 측분지(SB)의 기시부에 인접한 관상동맥의 협착을 말합니다. 난류와 높은 전단응력으로 인해 동맥경화성 플라크가 발생하기 쉬운 부위입니다. 그 치료에는 분석, 시술 시간, X선 피폭, 장기 추적 조사 등의 방법이 사용됩니다. 또한 분지각 측정에는 3차원(3D) 혈관조영술이나 멀티 슬라이스 CT가 활용되고 있습니다. 기기, 영상 진단, 보조 약물치료, 혈관 접근의 발전으로 복잡한 분지 병변의 경우 전 세계에서 치료가 가능해졌다.
분지 병변 시장 동향:
관상동맥질환(CAD)의 발생률이 눈에 띄게 증가함에 따라 분지 병변이 발생할 위험이 증가하고 있습니다. 이는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 이 외에도 혁신적인 의료기기의 승인, 보험 적용 범위 확대, 영상 진단 방법의 개선도 시장 성장을 촉진하고 있습니다. 또한 질병에 걸리기 쉬운 고령 인구의 증가와 더불어 각국 정부의 상환 지원책도 시장 성장을 지원하고 있습니다. 의료 관광의 증가, 최소침습(MI) 시술에 대한 수요 증가, 의료 인프라 개선도 시장 성장에 기여하는 또 다른 요인입니다. 이와 더불어 새로운 치료 기술에 대한 지속적인 연구가 시장을 주도하고 있습니다. 예를 들어 연구진은 합병증 위험이 높고 SB 폐색으로 인해 치명적인 결과를 초래할 수 있는 복잡한 분지 병변에 대한 Szabo 2-stent 방법의 효과를 조사하고 있습니다. 또한 스텐트 및 풍선에 대한 광범위한 임상 시험과 숙련된 의료진의 증가는 분지 병변 치료에 따른 위험을 감소시켜 시장에 긍정적인 영향을 미칠 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 분지병변 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 용도별
제8장 시장 내역 : 지역별
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
KSA 26.05.13The global bifurcation lesions market size reached USD 2.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.9 Billion by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2026-2034.
A bifurcation lesion refers to the narrowing of the coronary artery adjacent to the origin of a significant side branch (SB). It is prone to develop atherosclerotic plaque due to turbulent blood flow and high shear stress. It is treated using techniques like analysis, procedure duration, X-ray exposure, and long-term follow-up. Moreover, three-dimensional (3D) angiography and multi-slice computed tomography are utilized for measuring the bifurcation angles. With the advances in devices, imaging, adjunctive pharmacotherapy, and vascular access, the management of complex cases of bifurcation lesions is becoming possible worldwide.
BIFURCATION LESIONS MARKET TRENDS:
A significant rise in the occurrence of coronary artery disease (CAD) is increasing the risk of developing bifurcation lesions. This represents one of the key factors bolstering the market growth. Besides this, the approval of innovative devices, increasing insurance coverage, and improving imaging modalities are also strengthening the market growth. Moreover, the rising geriatric population, which is more likely to develop medical ailments, along with supportive initiatives undertaken by governments of various countries for reimbursement, is supporting the market growth. The increasing medical tourism, the escalating demand for minimally invasive (MI) procedures and the improving healthcare infrastructure are some of the other factors contributing to the growth of the market. Apart from this, the ongoing research on novel treatment techniques is driving the market. For instance, researchers are studying the effectiveness of the Szabo 2-stent technique for complex bifurcations lesions with high compromise risk or fatal consequences of SB occlusion. Furthermore, a wide range of clinical trials on stents and balloons, in confluence with the increasing number of skilled healthcare professionals, is anticipated to decrease risks associated with bifurcation lesions treatment and influence the market positively.
KEY MARKET SEGMENTATION:
Breakup by Types:
- One-Stent
- Two-Stent
Breakup by Application:
- Coronary Vascular
- Peripheral Vascular
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, Cardinal Health, Medtronic plc, Spectranetics (Koninklijke Philips N.V.) and Terumo Corporation.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. What was the size of the global bifurcation lesions market in 2025?
2. What is the expected growth rate of the global bifurcation lesions market during 2026-2034?
3. What has been the impact of COVID-19 on the global bifurcation lesions market?
4. What are the key factors driving the global bifurcation lesions market?
5. What is the breakup of the global bifurcation lesions market based on the application?
6. What are the key regions in the global bifurcation lesions market?
7. Who are the key players/companies in the global bifurcation lesions market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Bifurcation Lesions Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Types
- 6.1 One-Stent
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Two-Stent
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Application
- 7.1 Coronary Vascular
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Peripheral Vascular
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Boston Scientific Corporation
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Cardinal Health
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Medtronic plc
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Spectranetics (Koninklijke Philips N.V.)
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.5 Terumo Corporation
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.1 Boston Scientific Corporation
